DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Otezla is a prescription drug approved by the Food and Drug Administration (FDA) to treat active psoriatic arthritis and moderate to severe plaque psoriasis. Otezla is sometimes prescribed off-label for peripheral arthritis associated with spondylitis. Otezla may be referred to by its drug name, Apremilast.
Otezla is a disease-modifying antirheumatic drug (DMARD), a type of medication that suppresses the immune system and fights inflammation. Otezla is believed to work by inhibiting the production of tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
Otezla is generally taken twice a day.
Otezla comes in tablet form.
The FDA-approved label for Otezla lists common side effects including headache, cold symptoms, diarrhea, and nausea.
Rare but serious side effects listed for Otezla include depression and weight loss.
For answers to frequently asked questions about exposure to Otezla during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Otezla – Celgene